<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00861120</url>
  </required_header>
  <id_info>
    <org_study_id>2008-007799-13</org_study_id>
    <nct_id>NCT00861120</nct_id>
  </id_info>
  <brief_title>Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type</brief_title>
  <acronym>PaLiDo</acronym>
  <official_title>Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Wild-type</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vejle Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vejle Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the response rate in platinum-resistant, KRAS&#xD;
      wild-type, ovarian cancer patients who are treated with pegylated liposomal doxorubicin&#xD;
      (Caelyx®) in combination with biological treatment panitumumab (Vectibix®).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with platinum-resistant recurrent ovarian cancer have few therapeutic options and&#xD;
      the response rates are only 10-20% using non-cross-resistant chemotherapeutic agents.&#xD;
&#xD;
      New biologic agents in combination with chemotherapy or other treatment modalities may result&#xD;
      in improvement in survival.&#xD;
&#xD;
      Recent results in colorectal cancer have clearly indicated that KRAS mutant tumors do not&#xD;
      respond to treatment with EGFR inhibitors.&#xD;
&#xD;
      Panitumumab (ABX-EGF) is the first fully human monoclonal antibody specific to the EGF&#xD;
      receptor. To date, panitumumab has been evaluated in combination with chemotherapy in&#xD;
      patients with CRC, NSCLC, and SCCHN.&#xD;
&#xD;
      No previous studies have evaluated the effect of panitumumab in epithelial ovarian cancer&#xD;
      based on KRAS mutation status.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>6 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>6 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated liposomal doxorubicin</intervention_name>
    <description>40 mg/m2 on day 1 of a 28 days cycle</description>
    <other_name>Caelyx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>6 mg/kg on days 1 and 15 of a 28 days cycle</description>
    <other_name>Vectibix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed epithelial primary ovarian, primary fallopian or primary&#xD;
             peritoneal cancer. Stage I-IV.&#xD;
&#xD;
               -  A: First line treatment with a platinum containing regimen with either&#xD;
                  progression or no response during 1.line chemotherapy, or relapse within 6 months&#xD;
                  after end of 1. line chemotherapy, OR&#xD;
&#xD;
               -  B: Patients receiving second line with a platinum containing regimen with either&#xD;
                  progression or no response during second line chemotherapy, or relapse within 6&#xD;
                  months after end of second line chemotherapy&#xD;
&#xD;
          -  Maximum two prior lines of chemotherapy (both platinum-based)&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Performance status 0-2.&#xD;
&#xD;
          -  Measurable disease by CA125 GCIG criteria&#xD;
&#xD;
          -  KRAS wild type&#xD;
&#xD;
          -  Adequate bone marrow function, liver function, renal function and coagulation&#xD;
             parameters (within 7 days prior to randomization):&#xD;
&#xD;
               -  WBC ≥ 3.0 x 109/l or neutrophils (ANC)≥ 1.5 x 109/l&#xD;
&#xD;
               -  Platelet count ≥ 100 x 109/l&#xD;
&#xD;
               -  Hemoglobin ≥ 9.7 g/dl (6 mmol/L)&#xD;
&#xD;
               -  Serum bilirubin ≤ 1.5 x UNL&#xD;
&#xD;
               -  Serum transaminases ≤ 2.5 x UNL in absence of liver metastases, or ≤ 5xUNL in&#xD;
                  presence of liver metastases&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x UNL&#xD;
&#xD;
               -  Magnesium ≥ lower limit of normal&#xD;
&#xD;
               -  Calcium ≥ lower limit of normal&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with chemotherapy or biological targeted treatment except 1. line&#xD;
             chemotherapy with platinum or combination platinum/taxane (bevacizumab allowed as part&#xD;
             of the 1. line treatment).&#xD;
&#xD;
          -  Patients who have received (or are planning to receive) treatment with any other&#xD;
             investigational agent, or who have participated in another clinical trial within 28&#xD;
             days prior to entering this trial.&#xD;
&#xD;
          -  Pregnant or breast-feeding or planning to become pregnant within 6 months after end of&#xD;
             treatment. For fertile women a negative pregnancy test at screening is mandatory.&#xD;
&#xD;
          -  Fertile patients not willing to use acceptable and safe methods of contraception&#xD;
             during and for 6 months following treatment&#xD;
&#xD;
          -  Other present or previous malignancy except curatively treated cervical cancer,&#xD;
             non-melanotic skin cancer or other cancer with minimal risk of relapse.&#xD;
&#xD;
          -  CNS metastasis&#xD;
&#xD;
          -  History of any chronic medical or psychiatric condition or laboratory abnormality that&#xD;
             are not medically controlled or in the opinion of the Investigator may increase the&#xD;
             risks associated with study drug administration. (e.g. diabetes, cardiac diseases,&#xD;
             hypertension).&#xD;
&#xD;
          -  Clinically significant cardiovascular disease ≤ 1 year before&#xD;
             enrollment/randomization, including:&#xD;
&#xD;
               -  Myocardial infarction or unstable angina within 6 months of randomization.&#xD;
&#xD;
               -  New York Heart Association (NYHA) ≥ Grade 2 congestive heart failure. Even if&#xD;
                  medically controlled.&#xD;
&#xD;
               -  Poorly controlled cardiac arrhythmia despite Medication (patients with&#xD;
                  rate-controlled atrial fibrillation are eligible)&#xD;
&#xD;
          -  Uncontrolled hypercalcemia (calcium level outside the upper limit of normal;&#xD;
             antihypercalcemic treatment is allowed).&#xD;
&#xD;
          -  Allergy to the ingredients of the study medication or to Staphylococcus Protein A&#xD;
&#xD;
          -  History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial&#xD;
             lung disease on baseline chest CT scan.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Jakobsen, MD, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Vejle Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karina D. Steffensen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vejle Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AGO Austria</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leuven University Hospital</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aalborg Hospital</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herning Regional Hospital</name>
      <address>
        <city>Herning</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vejle Hospital, Dept. of Oncology</name>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>March 12, 2009</study_first_submitted>
  <study_first_submitted_qc>March 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2009</study_first_posted>
  <last_update_submitted>October 25, 2012</last_update_submitted>
  <last_update_submitted_qc>October 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian cancer</keyword>
  <keyword>KRAS wildtype</keyword>
  <keyword>Platinum resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Panitumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

